Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Phase 2
Recruiting
- Conditions
- Non-Muscle Invasive Bladder Urothelial CarcinomaNon-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- John Sfakianos
- Target Recruit Count
- 60
- Registration Number
- NCT06503614
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
News
No news found